Publications by authors named "Frederic Boisserie"
Article Synopsis
- The RATIONALE-301 study compared the cancer treatments tislelizumab and sorafenib in adults with unresectable hepatocellular carcinoma, finding tislelizumab met the goal of noninferiority in overall survival.
- The research utilized various health-related quality of life (HRQOL) assessments and revealed that patients on tislelizumab reported better HRQOL outcomes, particularly in aspects of fatigue and physical functioning, compared to those on sorafenib.
- Overall, tislelizumab not only showed better quality of life results but also had a favorable safety profile, marking it as a promising first-line treatment option for patients with hepatocellular carcinoma.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a major cause of cancer deaths, and there is a need for new first-line treatment options; tislelizumab, a PD-1 inhibitor, shows promise as a second-line treatment.
- The RATIONALE-301 clinical trial compares the efficacy and safety of tislelizumab and sorafenib in treating unresectable HCC in newly diagnosed patients.
- Results indicate that tislelizumab meets the criteria for noninferiority in overall survival compared to sorafenib, with a median overall survival of 15.9 months vs. 14.1 months; however, it did not demonstrate superiority, while showing a higher objective response rate (14.3%
Background: Bromodomain and extra-terminal (BET) proteins are epigenetic readers that can drive carcinogenesis and therapy resistance. RO6870810 is a novel, small-molecule BET inhibitor.
Methods: We conducted a Phase 1 study of RO6870810 administered subcutaneously for 21 or 14 days of 28- or 21-day cycles, respectively, in patients with the nuclear protein of the testis carcinoma (NC), other solid tumours, or diffuse large B-cell lymphoma (DLBCL) with MYC deregulation.
Article Synopsis
- * Monoclonal antibodies targeting PD-1 have shown promise in treating solid tumors, including HCC, with Tislelizumab being a notable investigational drug that binds specifically to PD-1.
- * The text discusses a Phase III study that compares the effectiveness, safety, and tolerability of Tislelizumab versus Sorafenib as first-line treatments for patients with unresectable HCC.
Purpose: Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC. A phase I study evaluated the combination with sorafenib in HCC.
Patients And Methods: In a 3 + 3 design, codrituzumab was given intravenously in various doses with sorafenib 400 mg twice daily to patients with advanced HCC, age ≥18, ECOG 0-1, Child-Pugh A and B7, adequate organ functions, and no prior systemic therapy, with tumor assessment by RECIST 1.
Background & Aims: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/FcγRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied vs. placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy.
View Article and Find Full Text PDFBackground: BRAF mutations are a validated target for cancer therapy. A second-generation BRAF inhibitor with an improved preclinical safety profile (RG7256) was evaluated in a first-in-man study in order to determine the safety, efficacy, pharmacokinetics and pharmacodynamics in patients with BRAF V600-mutated advanced solid tumors.
Patients And Methods: Patients received RG7256 orally over 8 dose levels from 200 mg once a day (QD) to 2400 mg twice a day (BID) (50-, 100- and 150-mg tablets) using a classic 3 + 3 dose escalation design.
Background: Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8-11 months while on treatment with the ALK inhibitor crizotinib. However, resistance inevitably develops, with the brain a common site of progression. More potent ALK inhibitors with consistently demonstrable CNS activity and good tolerability are needed urgently.
View Article and Find Full Text PDFBackground: Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the number of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may also prevent sporadic colorectal neoplasia.
Methods: We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily. Randomization was stratified for the use of low-dose aspirin.